Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis

Author(s): Ying Wu, Yi Yang, Haishan Wu, Beibei Zhang, Hui Tang, Jingping Zhao, Jindong Chen.

Journal Name: Current Signal Transduction Therapy

Volume 10 , Issue 1 , 2015

Become EABM
Become Reviewer


Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.

Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [4 - 9]
Pages: 6
DOI: 10.2174/1574362410666150311000100

Article Metrics

PDF: 53